



Hyperbaric Oxygen in the Treatment of Radiation Proctitis and Cerebral Necrosis



*Bora Uysal, Hakan Gamsız, Ferhat Dincoglan, Omer Sager, Selcuk Demiral and Murat Beyzadeoglu

Department of Radiation Oncology, Gulhane Education and Research Hospital, Turkey

Submission: October 24, 2017; Published: November 02, 2017

*Correspondence Address: Bora Uysal, Gulhane Education and Research Hospital, Department of Radiation Oncology, Etlik Kecioren 06018 Ankara, Turkey, Tel: +90 312 304 46 89; Fax: +90 312 304 46 89; Email: drborauysal@windowslive.com

Abstract

Background: Hyperbaric oxygen treatment is a challenging topic for radiation side effects.

Objective: The main goal is to evaluate the results of hyperbaric oxygen to treat proctitis and cerebral radionecrosis associated with radiotherapy.

Materials and Methods: 25 patients diagnosed with radiation proctitis and cerebral radionecrosis were treated with hyperbaric oxygen between 2008 January and 2017 February. 15 patients have radiation proctitis and 10 have cerebral radionecrosis. The symptoms of patients with radiation proctitis were stool frequency, hematochesia and pain. The presentation of others with cerebral radiation necrosis were headache, vertigo and dizziness. Hyperbaric oxygen of 2.4 Atmosphere Absolute was delivered for 25 patients.

Results: Stool frequency and pelvic pain in patients with proctitis was decreased after hyperbaric oxygen therapy. Symptoms of headache, vertigo and dizziness were better after hyperbaric oxygen. Also perinecrosal edema was limited and decreased with hyperbaric oxygen therapy.

Conclusion: Hyperbaric oxygen is an effective and useful therapy for radiation necrosis and proctitis.

Keywords : Hyperbaric oxygen; Radiation proctitis; Radiation necrosis

Introduction

Hyperbaric oxygen (HBO₂) therapy has been delivered for wide range of diseases in the literature. Firstly in 1950's, cervical cancer and head and neck tumors were the first usage of HBO₂ in addition to radiotherapy (RT). Tumor hypoxia is a major problem for radiotherapy management. It aggravates radioresistance. Hypoxic tumor cells are more radiosensitive compared to hypoxic ones. HBO₂ is an eminent agent that increases tumor oxygenation and it improves radiation results in many tumors. Brain necrosis, proctitis, laryngeal radionecrosis, optic neuropathy, soft tissue and bone injuries are the challenging issues of HBO₂ management in the cancer treatment era. Also HBO₂ was concomitantly used with photodynamic therapy and there was better tumor response at the end of this combination. Claustrophobia, cardiac and lung problems, pancytopenia etc. are the possible contraindications for HBO₂ management [1].

Material and Methods

This original retrospective article enrolls twenty five patients of radiation necrosis and proctitis treated with HBO₂ between January 2008 and February 2017. Fifteen of all had radiation proctitis and ten remaining patients had a cerebral necrosis. The patients with proctitis had stool caliber changes, diarrhea, stool frequency, hematochesia and pain. All fifteen

patients had grade 2 proctitis. Vertigo, dizziness, headache were the major symptoms of the group of radiation necrosis. Ten patients had grade 1 necrosis. Fifteen patients were diagnosed with rectum adenocarcinoma and they were treated with pelvic IGRT. 45 Gy was given for fourteen patients in 1.8 Gy per fraction and 50.4 Gy was delivered just for one patient in same daily fraction dose. Patients were managed with surgery six weeks after chemoradiotherapy. Adjuvant chemotherapy was delivered after surgery.

One patient with cerebral radionecrosis was treated with stereotactic surgery in the dose of 18 Gy. This patient had a radiological diagnosis of arteriovenous malformation. Other last nine patients with radionecrosis had a grade 2 astrocytoma and treated with 54 Gy per 200 cGy fraction after surgery. Surgery was total excision. 2.4 Atmosphere absolute (ATA) was given with multiplace hyperbaric chamber in 120 minutes for 25 patients. Patients were followed up with magnetic resonance spectroscopy (MR spectroscopy) or pelvic MR.

Results

24 patients (96%) of all were men and 1 (4%) of them was female (Table 1). Mean age was 30.6 (22-54). Stool frequency and pelvic pain was decreased and normalized after HBO₂ in

the patients with radiation proctitis. Symptoms of headache, vertigo and dizziness were got better in 10 patients of cerebral necrosis. Perinecrosal edema was decreased and limited after HBO₂. Patients were followed up for median 12 months (6-22). Preradiotherapy verbal numeric scale scores were median 6 (4-10) and postradiotherapy scores were median 3 (0-5) and it

was statistically significant (p<0.05). Median RT dose was 47.6 (18-54). 40% of all patients had grade 1 cerebral radionecrosis and 60% of all had grade 2 radiation proctitis. 11.1% of cerebral radionecrosis group had an arteriovenous malformation and 88.9% of remaining had a grade 2 astrocytoma (Table 2).

Table 1: Patient characteristics.

	Gender	Primary	RT dose	HBO dose	Purpose of HBO
P1	Male	Grade 2 Astrocytoma	54 Gy/2 Gy	2.4 ATA	Radiation necrosis
P2	Female	Rectum cancer	45 Gy/1.8 Gy	2.4 ATA	Radiation proctitis
P3	Male	Arteriovenous malformation	18 Gy/single dose SRS	2.4 ATA	Radiation necrosis
P4	Male	Rectum cancer	45 Gy/1.8 Gy	2.4 ATA	Radiation proctitis
P5	Male	Rectum cancer	50.4 Gy/1.8 Gy	2.4 ATA	Radiation proctitis
P6	Male	Rectum cancer	45 Gy/1.8 Gy	2.4 ATA	Radiation proctitis
P7	Male	Rectum cancer	45 Gy/1.8 Gy	2.4 ATA	Radiation proctitis
P8	Male	Rectum cancer	45 Gy/1.8 Gy	2.4 ATA	Radiation proctitis
P9	Male	Rectum cancer	45 Gy/1.8 Gy	2.4 ATA	Radiation proctitis
P10	Male	Grade 2 Astrocytoma	54 Gy/2 Gy	2.4 ATA	Radiation necrosis
P11	Male	Grade 2 Astrocytoma	54 Gy/2 Gy	2.4 ATA	Radiation necrosis
P12	Male	Grade 2 Astrocytoma	54 Gy/2 Gy	2.4 ATA	Radiation necrosis
P13	Male	Grade 2 Astrocytoma	54 Gy/2 Gy	2.4 ATA	Radiation necrosis
P14	Male	Grade 2 Astrocytoma	54 Gy/2 Gy	2.4 ATA	Radiation necrosis
P15	Male	Grade 2 Astrocytoma	54 Gy/2 Gy	2.4 ATA	Radiation necrosis
P16	Male	Grade 2 Astrocytoma	54 Gy/2 Gy	2.4 ATA	Radiation necrosis
P17	Male	Grade 2 Astrocytoma	54 Gy/2 Gy	2.4 ATA	Radiation necrosis
P18	Male	Grade 2 Astrocytoma	54 Gy/2 Gy	2.4 ATA	Radiation necrosis
P19	Male	Rectum cancer	45 Gy/1.8 Gy	2.4 ATA	Radiation proctitis
P20	Male	Rectum cancer	45 Gy/1.8 Gy	2.4 ATA	Radiation proctitis
P21	Male	Rectum cancer	45 Gy/1.8 Gy	2.4 ATA	Radiation proctitis
P22	Male	Rectum cancer	45 Gy/1.8 Gy	2.4 ATA	Radiation proctitis
P23	Male	Rectum cancer	45 Gy/1.8 Gy	2.4 ATA	Radiation proctitis
P24	Male	Rectum cancer	45 Gy/1.8 Gy	2.4 ATA	Radiation proctitis
P25	Male	Rectum cancer	45 Gy/1.8 Gy	2.4 ATA	Radiation proctitis

Table 2: HBO₂ indications.

	HBO ₂ indications
1	crush injury, compartment syndrome and other traumatic ischemias
2	Decompression sickness
3	Arterial insufficiencies
4	Acute thermal burn injury
5	Idiopathic sudden sensorineural hearing loss
6	Severe anemia
7	Intracranial abscess
8	Necrotizing soft tissue infections
9	Osteomyelitis
10	Delayed radiation injury
11	Compromised grafts and flaps
12	Air or gas embolism
13	Carbonmonoxide poisoning
14	Clostridial myositis and myonecrosis

Discussion

Radiation complications are categorized in acute, early-delayed and late-delayed injuries. Late injury enrolls radiation necrosis and leukoencephalopathy. Cytokines, reactiveoxygen species and vascular endothelial growth factors are leaked to the cell membrane by inflammatory activation [2]. Chemoradiotherapy combination and the increased usage of radiosurgery caused few more cases of radiation necrosis in brain tumors. It is hard to differentiate necrosis and recurrence with conventional Magnetic Resonance (MR) but MR Spectroscopy can be used for it. Bevacizumab is a novel agent to treat radiation necrosis [3].

Temporal lobe necrosis is unusual late complication of RT in nasopharyngeal carcinoma but IMRT and helical therapies decreased its incidence. Steroids, vitamins, surgery, anticolagulants, hyperbaric oxygen, bevacizumab are the major treatment methods for radiation necrosis [4]. In an article of 2012 update by Feldmeier et al. [5], one-third of patients with delayed radiation injuries get HBO₂ in United States. Supportive prophylactic usage of HBO₂ in high-risk patients was also discussed in this article. Gynecologic malignancies are one of the potential indications for the RT treatment. Late radiation effects and HBO₂ were reviewed in literature. Radiation proctitis, cystitis and necrosis should be managed with HBO₂. The effect of HBO₂ is decreased with the delaying time [6].

Retrospective series showed that not all but some patients with radiation necrosis of central nervous system were improved over their clinical or radiological findings after HBO₂. This result is conflictive and inconsistent but it shows that differential diagnosis should be made accurately and treatment algorithm could be started as soon as possible [7]. Preventive usage of HBO₂ in the management of radiation necrosis is discussed and it is not clear to start HBO₂ before or after symptoms or clinical

findings of necrosis [8]. In a series of 14 patients with gynecologic malignancy, it was shown that HBO₂ is effective, safe and well-tolerated management for soft tissue necrosis associated with radiation [9]. So important issue to be known is complications and side effects of HBO₂. These are ocular barotrauma, ear barotrauma, dental complications and myocardial infarction [10].

Radiation proctitis is a different and challenging topic. Topical medications and oral steroids should be recommended but HBO₂ and surgical interventions can be used after radiation proctitis. Improvements in radiation oncology techniques like IMRT and proton therapy lead to prevent rectal structures from radiation treatment. Also rectum spacers and balloons are still used by experts in some centers in the World [11]. Necrosis or proctitis after radiation possibly caused by decreased vascularity, hypoxia problems and leukocyte disfunction [12]. Treatment indications of HBO₂ are radiation necrosis, osteoradionecrosis, diabetic foot ulcer, osteomyelitis, failed flap or skin graft. One single center experience showed that nearly 82% of patients had better outcomes after HBO₂ [13].

In a study of 105 patients by Bui et al. [14], HBO₂ response rate was lower for salivary, neurologic, laryngeal and upper gastrointestinal symptoms compared to mucous membrane or soft tissue necrosis. High-dose steroids have been still used for radiation induced brain necrosis. HBO₂ treatment decreases steroid usage and clinical, sympomatic and radiological improvements were shown after HBO₂ in similar case studies [15,16]. One of the largest patient registry in literature was the study by Niezgoda et al. [17] 2358 patients were analyzed in this article and the most common injuries were osteoradionecrosis, dermal soft tissue radionecrosis, radiation cystitis, radiation proctitis and laryngeal radionecrosis in decreasing order. Continued therapeutic use of HBO₂ was supported and advised by authors in this large population study.

Radiosensitization of tumors with HBO₂ before radiotherapy was discussed in literature. Mayer et al wrote short overview of different centers and interval between HBO₂ and radiotherapy was 10-20 minutes [18]. HBO₂ decreases symptoms of cerebral necrosis, radiation proctitis and also improves life quality. Therapeutic role of HBO₂ was shown in the literature and randomized and multicenter studies are needed for future perspective of radiation complications and side effects. The results of our single center retrospective study are consistent with recent literature. Hyperbaric oxygen is an effective and useful therapy for radiation necrosis and proctitis.

Acknowledgement

No Financial support and sponsorship.

Conflict of Interest

There is no conflict of interest.

References

1. Al-Waili NS, Butler GJ, Beale J, Hamilton RW, Lee BY, et al. (2005) Hyperbaric oxygen and malignancies: a potential role in radiotherapy, chemotherapy, tumor surgery and phototherapy. *Med Sci Monit* 11(9): 279-289.
2. Fink J, Bom D, Chamberlain MC (2012) Radiation necrosis: relevance with respect to treatment of primary and secondary brain tumors. *Curr Neurol Neurosci Rep* 12(3): 276-285.
3. Chao ST, Ahluwalia MS, Barnett GH, Stevens GH, Murphy ES, et al. (2013) Challenges with the diagnosis and treatment of cerebral radiation necrosis. *Int J Radiat Oncol Biol Phys* 87(3): 449-457.
4. Chen J, Dassarat M, Yin Z, Liu H, Yang K, et al. (2011) Radiation induced temporal lobe necrosis in patient with nasopharyngeal carcinoma: a review of new avenues in its management. *Radiat Oncol* 6: 128.
5. Feldmeier JJ (2012) Hyperbaric oxygen therapy and delayed radiation injuries (soft tissue and bony necrosis): 2012 update. *Undersea Hyperb Med* 39(6): 1121-1139.
6. Allen S, Kilian C, Phelps J, Whelan HT (2012) The use of hyperbaric oxygen for treating delayed radiation injuries in gynecologic malignancies: a review of literature and report of radiation injury incidence. *Support Care Cancer* 20(10): 2467-2472.
7. Valadao J, Pearl J, Verma S, Helms A, Whelan H (2014) Hyperbaric oxygen treatment for post-radiation central nervous system injury: a retrospective case series. *Undersea Hyperb Med* 41(2): 87-96.
8. Kuffler DP (2012) Hyperbaric oxygen therapy: can it prevent induced necrosis. *Exp Neurol* 235(2): 517-527.
9. Williams JA Jr, Clarke D, Dennis WA, Dennis EJ, Smith ST (1992) The treatment of pelvic soft tissue radiation necrosis with hyperbaric oxygen. *Am J Obstet Gynecol* 167(2): 412-415.
10. Tahir AR, Westhuyzen J, Dass J, Collins MK, Webb R, et al. (2015) Hyperbaric oxygen therapy for chronic radiation-induced tissue injuries: Australasia's largest study. *Asia Pac J Clin Oncol* 11(1): 68-77.
11. Vanneste BG, Van De Voorde L, De Ridder RJ, Van Limbergen EJ, Lambin P, et al. (2015) Chronic radiation proctitis: tricks to prevent and treat. *Int J Colorectal Dis* 30(10): 1293-1303.
12. Mathes SJ, Alexander J (1996) Radiation Injury. *Surg Oncol Clin N Am* 5(4): 809-824.
13. Skeik N, Porten BR, Isaacson E, Seong J, Klosterman DL, et al. (2015) Hyperbaric oxygen treatment outcome for different indications from a single center. *Ann Vasc Surg* 29(2): 206-214.
14. Bui QC, Lieber M, Withers HR, Corson K, Van Rijnsoever M, et al. (2004) The efficacy of hyperbaric oxygen therapy in the treatment of radiation-induced late side effects. *Int J Radiat Oncol Biol Phys* 60(3): 871-878.
15. Cihan YB, Uzun G, Yildiz S, Donmez H (2009) Hyperbaric oxygen therapy for radiation-induced brain necrosis in a patient with primary central nervous system lymphoma. *J Surg Oncol* 100(8): 732-735.
16. Kohski K, Imada H, Nomoto S, Yamaguchi R, Abe H, et al. (2003) Successful treatment of radiation-induced brain necrosis by hyperbaric oxygen therapy. *J Neurol Sci* 209(1-2): 115-117.
17. Niezgoda JA, Serena TE, Carter MJ (2016) Outcomes of radiation injuries using hyperbaric oxygen therapy: an observational cohort study. *Adv Skin Wound Care* 29(1): 12-19.
18. Mayer R, Hamilton-Farrell MR, van der Kleij AJ, Schmutz J, Granström G, et al. (2005) Hyperbaric oxygen and radiotherapy. *Strahlenther Onkol* 181(2): 113-123.



This work is licensed under Creative Commons Attribution 4.0 License
DOI: [10.19080/CTOIJ.2017.07.555720](https://doi.org/10.19080/CTOIJ.2017.07.555720)

Your next submission with Juniper Publishers will reach you the below assets

- Quality Editorial service
- Swift Peer Review
- Reprints availability
- E-prints Service
- Manuscript Podcast for convenient understanding
- Global attainment for your research
- Manuscript accessibility in different formats
(Pdf, E-pub, Full Text, Audio)
- Unceasing customer service

Track the below URL for one-step submission
<https://juniperpublishers.com/online-submission.php>